Tislelizumab Mechanism of Action
MOA Resources
Reimagining Medicine for Patients With GI Cancers
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data.
Explore Clinical Trials
Explore Clinical Trials
1L mPDAC
daNIS-1
Phase II Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in 1L mPDAC
1L mPDAC
daNIS-2
Phase III Study of NIS793 in Combination With SOC Chemotherapy in 1L mPDAC
2L mCRC
daNIS-3
Phase II Study of NIS793 and Other Novel Investigational Combinations with SOC Anti-cancer Therapy for 2L Treatments of mCRC
mCRC, mGEC, mRCC
NCT03798626
Phase 1b Study of Gevokizumab in Combination with SOC Anti-Cancer Therapies in Patients with mCRC, mGEC, and mRCC
Explore Compounds
Explore Compounds
Spartalizumab (PDR001)
PD-1–targeting monoclonal antibody
